Clinical Trial Detail

NCT ID NCT02810418
Title Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

malignant epithelial mesothelioma

Advanced Solid Tumor

pancreatic ductal adenocarcinoma

Therapies

LMB-100

LMB-100 + Nab-paclitaxel

Age Groups: senior adult

No variant requirements are available.